Log In
Print
BCIQ
Print
Print this Print this
 

ALN-ANG

  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionSubcutaneous formulation of small interfering RNA (siRNA) against angiopoietin-like 3 (ANGPTL3)
Molecular Target Angiopoietin-like 3 (ANGPTL3)
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPreclinical
Standard IndicationHyperlipidemia
Indication DetailsTreat genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today